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the patient. Although parallel group, randomised controlled
trials (RCTs) are the gold standard for generating evidence
about group treatment efficacy, such evidence is not always
available or relevant for individual treatment decisions.
Many scenarios exist where this holds true. As examples,
unique challenges exist with respect to evaluating treatments
in populations with rare diseases; adequate recruitment for
group trials is not always feasible, retention may be difficult,
and funding may be difficult to obtain [1,2]. Similarly, chil-
dren, adolescents, and elderly people are typically excluded* Corresponding author. Tel.: 780-492-6445; fax: 780-492-5883.
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0895-4356/ 2015 The Authors. Published by Elsevier Inc. This is an open acces
by-nc/4.0/).from or not studied in large scale RCTs [1,3]. Patients with
comorbid conditions or receiving concurrent therapies are
also understudied because of stringent inclusion protocols
in RCTs. Exclusions of these groups may occur for safety
reasons, but more often exclusions according to strict eligi-
bility criteria occur in order to ensure a homogenous sample
in the hope of increasing the likelihood of demonstrating a
treatment effect [4,5]. Unfortunately, the patient groups
described above comprise the majority, rather than a subset,
of the clinical population, and information to guide their
treatment decisions is sparse [3,6,7].
Difficulty in measuring and accounting for heterogeneity
provides another reason why group trials may not always be
the best choice of study design. Summary data fromgroup tri-
als likely contains some level of heterogeneity and may nots article under the CC BY-NC license (http://creativecommons.org/licenses/
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there is a clear overall benefit at the group level, it may not
benefit individual patients equally, or at all (Fig. 1). N-of-1
trials provide a mechanism to evaluate the effects of treat-
ment for an individual; when trials of individuals are
combined using the right statistical techniques, they may
be able to approximate effect estimates from group data [8].
In the context of making decisions about an individual
patient’s care, N-of-1 trials have been considered to be
among the most relevant and rigorous study designs for as-
sessing treatment efficacy; they are listed as ‘‘level 1’’ ev-
idence in the Oxford Center for Evidence-Based Medicine
2011 levels of evidence [9,10]. As with crossover trials,
N-of-1 trials eliminate confounding by covariates since
each patient serves as his or her own control. The use of
multiple crossovers within well designed N-of-1 trials
[11] increases confidence in the reliability of the results.
In addition to their value in evidence based clinical prac-
tice, N-of-1 trials also have a valuable role in advancing
medical research evidence. For example, researchers might
conduct a series of N-of-1 trials to inform overall treatment
effect for a group, while simultaneously obtaining relevant
treatment information for individual participants. Further-
more, N-of-1 trials might be useful in personalised medi-
cine research to explore subgroups that have differingFig. 1. Illustration of how overall benefit at the group level may not
benefit individual patients equally. Panel A shows no interaction be-
tween patients and treatment, where all individuals improve by the
same amount; panel B shows interaction between patients and treat-
ment such that each patient improves by an individual amount.responses to treatment, complementing the emerging field
of pharmacogenomics research. If done and reported well,
N-of-1 trials can make a worthwhile contribution to patient
centered research, as they can empower patients to partici-
pate actively in selecting their treatment options.
Poor reporting, labeling, and indexing of N-of-1 trials has,
to date, prevented an accurate estimate of the prevalence of
trials in the literature. None the less, N-of-1 trials have been
documented evaluating a range of health conditions,
including mental and behavioral disorders and diseases of
the nervous, respiratory, circulatory, musculoskeletal, and
digestive systems [12]. They have also been used to evaluate
a variety of interventions, whether pharmacological or non-
pharmacological, including complementary or alternative
therapies. Most documented trials are being done in Western
regions (North America, Europe, and Australia).1. Defining ‘‘N-of-1’’ trials
The term ‘‘N-of-1 trial’’ is shared between the fields of
medicine and behavioral science, but refers to different
concepts within each.
N-of-1 trials are a well established and extensively used
experimental design in the behavioral sciences [13e15].
The term is often used to refer to a range of single case
experimental designs (Fig. 2) [16,17].
In medicine, ‘‘N-of-1’’ largely refers to a specific trial
designdone using a repeated cycle of treatment challenge
and withdrawal (A-B-A-B) in a single participant, where
one period (‘‘A’’) is the treatment being studied and the
other period (‘‘B’’) is a comparison treatment, a control,
or no intervention [18]. This design is sometimes described
as ‘‘ABAB’’ and may incorporate key elements of RCTs
used to reduce bias such as randomisation (of treatment
sequence) and blinding (of patient, care provider, outcome
assessor, and data analysts). In the remainder of this docu-
ment, the term ‘‘N-of-1 trial’’ will refer to a prospective,
multiple crossover ABAB, single participant trial used in
medicine. Terms often used to describe methodological as-
pects of N-of-1 trials are provided in Box 1.2. Evidence of incomplete and inaccurate reporting
The reporting of key elements of N-of-1 trials varies, as
characterised in a recent systematic review of N-of-1 trials
examining health interventions for medical or clinical con-
ditions, identifying 100 reports for inclusion: 60 series of
several N-of-1 trials and 40 individual trials [12]. Although
randomisation is not essential in N-of-1 trials, trials that
were labeled as randomised (n5 71) described the methods
of sequence generation only 30% of the time and failed to
indicate whether allocation concealment was used 76% of
the time. Perhaps more concerning is that a primary
outcome was not indicated in 79% of included reports,
Fig. 2. Common single case designs. CENT is applicable to a subset of the ‘‘Withdrawal/reversal designs’’ category, which may or may not include
the use of randomisation, designated by the red ‘‘N-of-1’’ box (adapted from [17]). (For interpretation of references to color in this figure legend,
the reader is referred to the web version of this article.)
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occurred. Most trials reported the use of statistical analyses
(n 5 75), and, of these, 89% reported summary measures,
yet only 49% provided estimates of precision. Reporting of
other important trial characteristics that may lead to bias in
the interpretation of results, such as whether carryover ef-
fect or period effect were assessed, were not reported in
91% and 97% of trials, respectively.
These findings are in line with an earlier systematic re-
view of 108 medical N-of-1 trials, in which less than half
(45%) reported enough information to enable meta-
analysis; specific missing elements were measures of vari-
ance and precision [19]. Furthermore, 47% of trials did not
provide any numerical estimate of effect size.
Failure to report key elements of the methods and re-
sults for N-of-1 trials impedes readers’ assessment of
the validity of the research and prevents clinicians and
researchers from making optimal use of N-of-1 trial find-
ings in clinical care and future research. The CENT 2015
guidance is in line with the recent international efforts to-
ward better reporting of health research overall [20], and
authors are encouraged to make use of it when preparing
their reports of individual or series of N-of-1 trials. Like-
wise, those charged with reviewing N-of-1 trials for pub-
lication (that is, made publicly available in some form) are
urged to use CENT to ensure that information is complete
before acceptance.3. Scope of CENT 2015
The CENT 2015 guidance is aimed at facilitating the re-
porting of primary N-of-1 trialsdindividual trials and pro-
spective series of N-of-1 trials. It is not, however, intended
to address the reporting of retrospective syntheses (that is, sys-
tematic reviews ormeta-analyses) of data from separate N-of-
1 trial reports. Box 2 clarifies the distinction between primary
and secondary studies. CENT is also not intended for other
single case experimental design studies used in behavioralmedicine.Additional guidance for these types of studies is un-
der way [21] or planned by members of the CENT group.4. CONSORT 2010
The CONSORT (Consolidated Standards Of Reporting
Trials) Statement was among the first consensus based re-
porting guidelines to appear in the mid-1990s and has since
been updated, most recently in 2010, to remain in line with
new evidence and opinion [22]. It is intended to provide au-
thors with a minimum set of items that should be addressed
in reports of two arm, parallel group, clinical trials. The lat-
est iteration, CONSORT 2010, consists of a 25 item check-
list (37 items including sub-items) and a flow diagram
illustrating how to document participants’ flow through a
trial. It has received widespread support within the biomed-
ical publishing community (endorsed by over 600 journals),
and its endorsement is associated with more completely re-
ported trials [23].
CENT 2015 is an official extension of the CONSORT
2010 Statement and can be found, along with other exten-
sions, on the CONSORT website (www.consort-statement.
org). For journals wishing to endorse CENT 2015, please
see the CENT 2015 Statement for recommended text to
include in journal ‘‘instructions to authors’’ text [24].5. Overview of checklist development
Selection of candidate checklist items was informed by
the aforementioned systematic review [12] and by the CON-
SORT 2010 checklist. Checklist development followed the
general process recommended by the Enhanced Quality
and Transparency of Reporting (EQUATOR) Network for
developing a reporting guideline [25], in which consensus
is a fundamental component. A two-round Delphi survey
of 56 expertsdincluding N-of-1 trialists, epidemiologists,
reporting guideline developers, biomedical journal editors,
and fundersdpreceded an in-person consensus meeting of
Box 1 Methodological terminology typical in
N-of-1 trial reports
N-of-1 trialdAn experimental clinical study design
to determine the effect of an intervention in a single
study participant. CENT is intended to be used to
report repeated challenge-withdrawal (that is,
‘‘ABAB’’) trials, commonly used in medicine, in
which multiple crossovers between treatment(s) and
control (placebo, standard care, alternate treatment)
are continued for a pre-specified amount of time or
until treatment effectiveness is determined. More
than two treatment alternatives may be compared to
each other or control (that is, ‘‘ABCABC’’)
PerioddThe time during which a single treatment (A
or B) is administered. Period length is typically deter-
mined a priori and may vary within a trial. The order
of periods within a pair or treatment block may be
randomised.
Block or pairdA repeated unit of a set number of
period in N-of-1 trials is referred to as a block, in
which the sequence of periods may or may not be
randomised (for example, three repeating blocks of
four periods may look like ‘‘AABB BBAA ABAB’’).
By convention, when the repeated unit contains only
two periods (for example, three repeating pairs may
look like ‘‘AB BA BA’’), it is conventionally referred
to as a pair.
SequencedMultiple pairs or blocks comprise an
entire sequence. The sequence is the consecutive set
of periods, which may or may not indicate size of
the repeated unit.
Washout perioddA period in which no intervention
is administered. A washout may be administered be-
tween different treatment periods or may act as a
period in itself, as in a ‘‘reversal’’ design (to ‘‘wash
out’’ the effects of a treatment before it is re-
administered).
Run-in perioddA pre-specified duration of time
before a trial begins, during which trial treatments
may be initiated (for example, to get to a stable ther-
apeutic dose), to determine potential patient compli-
ance with study regimens, or to allow for washout
of a medication(s) a patient may have been taking
before the trial.
Box 2 Terminology used to describe primary and
secondary reports of N-of-1 trials
N-of-1 trialdA prospective, multiple crossover (that
is, ABAB) trial in a single participant.
Series of N-of-1 trialsdA prospectively planned set
of N-of-1 trials designed to evaluate the same clinical
question across individuals. A report of a series of N-
of-1 trials may include quantitative synthesis such as
meta-analysis.
Systematic review of N-of-1 trialsdA systematic
collection of N-of-1 trials in a single report using
explicit a priori methodology including systematic
identification, data collection, and analyses processes.
Data from individual trials may be synthesised using
narrative or, in certain circumstances, meta-analytic
methods.
Quantitative synthesis or meta-analysis of N-of-1
trialsdThe statistical synthesis of data from more
than one N-of-1 trial; may be a component of an N-
of-1 series, systematic review, or literature review
of N-of-1 trials.
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the CENT development process can be found in the CENT
Statement [24]. All CENT related guidance documents have
undergone an iterative refinement process within the CENT
steering committee (DGA, Nick Barrowman, CB, DM, JN,MS, LS, RT, SV) and larger CENT group listed at the end
of this document. LS and SV led the writing of this docu-
ment and members of the CENT group contributed to the
writing and identification of relevant examples contained
within this document. A subcommittee was also convened
to develop the CENT diagrams (NBG, JN, DZ).6. CENT 2015 checklist
The CENT 2015 checklist is an extension of 14 items of
the 25 CONSORT 2010 items (Table 1). Of the 25 items of
the CONSORT 2010 checklist, 12 are further divided into
sub-items, creating a total 37 sub-items. With the modifica-
tions and additions to CONSORT 2010 items, there are 44
sub-items in the CENT checklist, some of which only
pertain to series of trials (as indicated). For item 1b, per-
taining to the reporting of abstracts, specific recommenda-
tions for N-of-1 trials are proposed in Table 2.
The recommendations within CENT may require more
words and space than N-of-1 trialists are accustomed to.
Providing detailed descriptions for some trials will facilitate
transparency and future reproducibility, in line with
emerging journal policies aimed at facilitating reproduc-
ibility [26].
We recognise that improved reporting must be
balanced against patient confidentiality in situations
when the condition is rare. Authors must be mindful of
this, and if there is any doubt as to whether complete re-
porting could be potentially identifying, they should seek
Table 1. CENT 2015 checklista; CONSORT 2010 checklist items with modifications or additions for individual or series of N-of-1 trials; empty
items in the CENT 2015 column indicate no modification from the CONSORT 2010 item
Section/Topic
CONSORT 2010 CENT 2015
No Item No Item
Title and abstract
1a Identification as a randomised trial in the title 1a Identify as an ‘‘N-of-1 trial’’ in the title
For series: Identify as ‘‘a series of N-of-1 trials’’
in the title
1b Structured summary of trial design, methods,
results, and conclusions (for specific guidance
see CONSORT for abstracts)
1b For specific guidance, see CENT guidance for
abstracts (Table 2)
Introduction
Background and
objectives
2a Scientific background and explanation of
rationale
2a.1
2a.2 Rationale for using N-of-1 approach
2b Specific objectives or hypotheses 2b
Methods
Trial design 3a Description of trial design (such as parallel,
factorial) including allocation ratio
3a Describe trial design, planned number of
periods, and duration of each period
(including run-in and wash out, if applicable)
In addition for series: Whether and how the
design was individualized to each participant,
and explain the series design
3b Important changes to methods after trial start
(such as eligibility criteria), with reasons
3b
Participant(s) 4a Eligibility criteria for participants 4ab Diagnosis or disorder, diagnostic criteria,
comorbid conditions, and concurrent
therapies.
For series: Same as CONSORT item 4a
4b Settings and locations where the data were
collected
4bb
4c Whether the trial(s) represents a research study
and if so, whether institutional ethics approval
was obtained
Interventions 5 The interventions for each group with sufficient
details to allow replication, including how and
when they were actually administered
5 The interventions for each period with sufficient
details to allow replication, including how and
when they were actually administered
Outcomes 6a Completely defined pre-specified primary and
secondary outcome measures, including how
and when they were assessed
6a.1
6a.2 Description and measurement properties
(validity and reliability) of outcome
assessment tools
6b Any changes to trial outcomes after the trial
commenced, with reasons
6b
Sample size 7a How sample size was determined 7a
7b When applicable, explanation of any interim
analyses and stopping guidelines
7b
Randomisation
Sequence generation 8a Method used to generate the random allocation
sequence
8a Whether the order of treatment periods was
randomised, with rationale, and method used
to generate allocation sequence
8b Type of randomisation; details of any restriction
(such as blocking and block size)
8b When applicable, type of randomisation; details
of any restrictions (such as pairs, blocking)
8c Full, intended sequence of periods
Allocation concealment
mechanism
9 Mechanism used to implement the random
allocation sequence (such as sequentially
numbered containers), describing any steps
taken to conceal the sequence until
interventions were assigned
9
Implementation 10 Who generated the random allocation sequence,
who enrolled participants, and who assigned
participants to interventions
10
(Continued )
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Table 1. Continued
Section/Topic
CONSORT 2010 CENT 2015
No Item No Item
Blinding 11a If done, who was blinded after assignment to
interventions (for example, participants, care
providers, those assessing outcomes) and how
11a
11b If relevant, description of the similarity of
interventions
11b
Statistical methods 12a Statistical methods used to compare groups for
primary and secondary outcomes
12a Methods used to summarize data and compare
interventions for primary and secondary
outcomes
12b Methods for additional analyses, such as
subgroup analyses and adjusted analyses
12b For series: If done, methods of quantitative
synthesis of individual trial data, including
subgroup analyses, adjusted analyses, and
how heterogeneity between participants was
assessed (for specific guidance on reporting
syntheses of multiple trials, please consult the
PRISMA Statement)
12c Statistical methods used to account for carryover
effect, period effects, and intra-subject
correlation
Results
Participant flow
(a diagram is strongly
recommended)
13a For each group, the numbers of participants who
were randomly assigned, received intended
treatment, and were analysed for the primary
outcome
13a.1 Number and sequence of periods completed, and
any changes from original plan with reasons
13a.2 For series: The number of participants who were
enrolled, assigned to interventions, and
analysed for the primary outcome
13b For each group, losses and exclusions after
randomisation, together with reasons
13c For series: Losses or exclusions of participants
after treatment assignment, with reasons, and
period in which this occurred, if applicable
Recruitment 14a Dates defining the periods of recruitment and
follow-up
14ab
14b Why the trial ended or was stopped 14b Whether any periods were stopped early and/or
whether trial was stopped early, with
reason(s).
Baseline data 15 A table showing baseline demographic and
clinical characteristics for each group
15b
Numbers analysed 16 For each group, number of participants
(denominator) included in each analysis and
whether the analysis was by original assigned
groups
16 For each intervention, number of periods
analysed.
In addition for series: If quantitative synthesis
was performed, number of trials for which data
were synthesized
Outcomes and
estimation
17a For each primary and secondary outcome, results
for each group, and the estimated effect size
and its precision (such as 95% confidence
interval)
17a.1 For each primary and secondary outcome, results
for each period; an accompanying figure
displaying the trial data is recommended.
17a.2 For each primary and secondary outcome, the
estimated effect size and its precision (such as
95% confidence interval)
In addition for series: If quantitative synthesis
was performed, group estimates of effect and
precision for each primary and secondary
outcome
17b For binary outcomes, presentation of both
absolute and relative effect sizes is
recommended
17b
Ancillary analyses 18 Results of any other analyses performed,
including subgroup analyses and adjusted
analyses, distinguishing pre-specified from
exploratory
18 Results of any other analyses performed,
including assessment of carryover effects,
period effects, intra-subject correlation
In addition for series: If done, results of
subgroup or sensitivity analyses
(Continued )
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Table 1. Continued
Section/Topic
CONSORT 2010 CENT 2015
No Item No Item
Harms 19 All important harms or unintended effects in
each group (for specific guidance see
CONSORT for harms)
19 All harms or unintended effects for each
intervention. (for specific guidance see
CONSORT for harms)
Discussion
Limitations 20 Trial limitations, addressing sources of potential
bias, imprecision, and, if relevant, multiplicity
of analyses
20
Generalisability 21 Generalisability (external validity, applicability)
of the trial findings
21
Interpretation 22 Interpretation consistent with results, balancing
benefits and harms, and considering other
relevant evidence
22
Other information
Registration 23 Registration number and name of trial registry 23
Protocol 24 Where the full trial protocol can be accessed, if
available
24
Funding 25 Sources of funding and other support (such as
supply of drugs), role of funders
25
a It is strongly recommended that this checklist be read in conjunction with the CENT 2015 Explanation and Elaboration24 for important clar-
ification on the items. The copyright for CENT (including checklist) is held by the CENT Group and is distributed under a Creative Commons Attri-
bution (CC-BY 4.0) license.
b Caution should be taken when reporting potentially identifying information pertaining to CENT items 4a, 4b, 14a, and 15.
24 L. Shamseer et al. / Journal of Clinical Epidemiology 76 (2016) 18e46consultation with their institutional ethics board. This
issue is of heightened importance in N-of-1 trials of rare
conditions or when the potential societal stigma is high.Table 2. CENT abstract considerations (modifications or additions to CONS
Item CONSORT for abstracts
Title Identification of the study as randomised
Authorsa Contact details for the corresponding author
Trial design Description of trial design (such as parallel, c
non-inferiority)
Methods:
Participant(s) Eligibility criteria for participants and the sett
where the data were collected
Interventions Interventions intended for each group
Objective Specific objective or hypothesis
Outcome Clearly defined primary outcome for this repor
Randomisation How participants were allocated to interventio
Blinding (masking) Whether participant(s), care givers, and those a
the outcomes were blinded to group assignm
Results:
Numbers randomised Number of participants randomised to each gr
Recruitment Trial status
Numbers analysed Number of participants analysed in each grou
Outcome For the primary outcome, a result for each grou
estimated effect size and its precision
Harms Important adverse events or side-effects.
Conclusions General interpretation of the results
Trial registration Registration number and name of trial register
applicable
Funding Source of funding
a For conference abstracts.Caution should be taken when reporting a combination
of identifying information pertaining to CENT items 4a,
4b, 14a, and 15.ORT Statement for Abstracts)
Extension for N-of-1 designs
Identification of the study as an N-of-1 trial or series of
N-of-1 trials in the title
luster, Description of trial design, number of periods, and
period duration
ings For individual trial, clinical condition under study
For series, eligibility criteria for participants
Interventions intended for each period
t
ns
ssessing
ent
oup For individual N-of-1 trial, the number and sequence of
periods completed
For series, number of individual trials carried out
Not applicable
p For individual N-of-1 report, number of periods
analysed for each intervention
For series, the number of participants analysed
p and the
, if
Fig. 3. N-of-1 trial pictorial; suggested visual representation of data
from an individual N-of-1 trial.
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In the spirit of the CONSORT 2010 flow diagram, two di-
agrams specifically for CENT have been developed to help
authors visually depict participant progress and outcomes
through an individual trial (Fig 3) and the flow of participants
in a series of trials (Fig 4). We recommend that authors
include these diagrams, as appropriate, in reports of N-of-1
trials; specific guidance on the information to include in each
is provided in items 17a.1 and 13a.1, respectively.8. CENT explanation and examples
In the remainder of this document we provide explana-
tions of each CENT 2015 checklist item with examples ofFig. 4. CENT flow diagram; suggested representation of the flow of
participants in a series of N-of-1 trials.good reporting. While many CENT 2015 items refer directly
to CONSORT 2010 items, examples from N-of-1 trials are
still provided to give an example of reporting in the context
of N-of-1 trials. Where we felt it was necessary, a rationale
is provided for specific nuances associated with reporting
N-of-1 trials. We have tried to provide examples of reporting
from both series and individual N-of-1 trial reports, where
applicable and available. For a comprehensive understanding
of reporting of an N-of-1 trial, we strongly recommend that
this explanatory document be read together with the CON-
SORT 2010 Explanation and Elaboration document [27].
As noted, the authors of many N-of-1 trials fail to report
essential information, leaving a small pool of studies from
which to draw examples of complete reporting [12]. Rather
than constructing hypothetical examples of reporting that
do not exist in the literature, we rely more heavily on exam-
ples from reports of series of trials. For some items, no
example of good reporting could be identified. As the
CENT guideline becomes established and has an impact
on N-of-1 trial reporting, this document will be updated
to include a more comprehensive and relevant set of
examples.
Finally, for convenience, we will refer to treatments and
patients throughout this document, although we recognise
that not all interventions evaluated in N-of-1 trials are tech-
nically treatments and trial participants are not always pa-
tients. All citations within included examples have been
removed for ease of reading.9. Title and abstract
Item 1a
Standard CONSORT item: Identification as a rando-
mised trial in the title
CENT extension: Identification as an ‘‘N-of-1 trial’’ in
the title
Example: ‘‘An N-of-1 randomized controlled trial
(‘N-of-1 trial’) of donepezil in the treatment of non-
progressive amnestic syndrome’’ [28].
For series: Identification as a ‘‘series of N-of-1 trials’’ in
the title
Example: ‘‘Efficacy of temazepam in frequent users: a
series of N-of-1 trials’’ [29].
Explanation: In order for an N-of-1 trial or a series of
trials to be easily identified in an electronic database search,
the title, at minimum, should contain prominent, recognis-
able terminology. For instance, the potential for N-of-1
trials to be quantitatively synthesised will largely depend
on whether they can be reliably identified in the literature.
Including ‘‘N-of-1 trial’’ or ‘‘series of N-of-1 trials’’ in the
title of a report will ensure that they are consistently iden-
tified, regardless of the capabilities of the search interface.
Since N-of-1 trials are currently described using heteroge-
neous terminology (such as single case experimental study,
single patient trials, etc.), the use of ‘‘N-of-1’’ is advised to
26 L. Shamseer et al. / Journal of Clinical Epidemiology 76 (2016) 18e46refer to the specific N-of-1 trial design (that is, ABAB)
around which CENT is based (that is, prospective, multiple
crossover).
Item 1b
Standard CONSORT item: Structured summary of trial
design, methods, results, and conclusions (for specific guid-
ance see CONSORT for abstracts)
CENT extension: see CENT guidance for abstracts
(Table 2)
Example:
‘‘Introduction: There are several substances available
which are used for prophylaxis in patients suffering from
migraine. To test the effects of second choice drugs (e.g.
in case of side effects of first line substances) reliably,
n-of-1 trial on a single patient is one viable option.
Feverfew (Tanacetum parthenium L.) is a plant of the fam-
ily of chrysanthemum. It is known as well under ‘wrong
chamomile’ and can be used for prophylaxis of migraine.
Material andMethods: 100mg extract of feverfew (verum)
and 100 mg lactose (placebo) were manufactured in identical
caps for a single female patient and taken for 2weeks each.Af-
ter this time, both substances were taken in reverse order. The
patient documented on a daily basis whether she had headache
and noted the intensity of the pain. The experimental assembly
was planned in a double blind design.
Results: During placebo intake, the patient suffered from
3.0 attacks of migraine on a weekly average, while verum
(feverfew) reduced the number of attacks to 1.5 per week.
During placebo intensity of migraine attacks averaged 3.0
units on a Likert Scale (0 5 no pain, 6 5 maximal conceiv-
able pain), during verum the respective value was 1.6. The
pain intensity was approximately twice as high while taking
placebo compared to verum.
Conclusion:Use of feverfew showed clear efficacy in this
patient on the basis of an experimental n-of-1 trial. Reduction
of attack rate and pain intensity alike was over 50%.’’ [30].
Explanation: While the suggested abstract structure
remains the same as CONSORT 2010 (item 1a), there are
some differences in content to be considered in abstracts
of N-of-1 trial reports. CENT-specific guidance, adapted
from the 2008 CONSORT extension for journal and confer-
ence abstracts [31], is proposed in Table 2.10. Introduction
Item 2a
Standard CONSORT item: Scientific background and
explanation of rationale
CENT extension: Replaced by item 2a.1 and 2a.2.
Item 2a.1 CENT extension: No change from CONSORT
item 2a
Example:
‘‘Chronic obstructive pulmonary disease (COPD) is a
leading cause of morbidity and mortality worldwide and
results in substantial economic and social burden. Manypatients with COPD identify dyspnea on exertion as the
key adverse impact of their condition and the strongest
determinant of their functional status. Several guidelines
have suggested that COPD management should be individ-
ualized and based on assessments of the impact of treat-
ment on dyspnea rather than on physiological measures
of pulmonary function or arterial blood gases.
A Cochrane review has summarized the well recognized
mortality benefits of long term oxygen therapy (LTOT) for
individuals with chronic resting hypoxemia. Clinicians
sometimes prescribe ambulatory oxygen for patients
without resting hypoxemia, who experience hypoxemia on-
ly during exercise or activities of daily living. Studies of
short term ambulatory oxygen have demonstrated improve-
ments in acute exercise performance among patients with
moderate to severe COPD. However, these laboratory
based, acute physiological responses may not reflect how
a patient responds symptomatically to the longer term use
of ambulatory oxygen in their daily lives.
Justifying the expense and inconvenience of long term
ambulatory oxygen for transient exercise hypoxemia re-
quires an understanding of its effect on the patient’s expe-
rience in the community, during activities of daily living.
Four randomised controlled trials (RCTs), evaluating the
role of ambulatory oxygen, have reported mixed results.’’
[32].
Explanation: This item emphasises the importance of
providing a rationale for the broader study question, unre-
lated to N-of-1 design. For a detailed explanation, please
refer to item 2a in the CONSORT 2010 explanatory docu-
ment. For explanation of the decision to use N-of-1 trial
design please refer to CENT 2015 item 2a.2.
Item 2a.2 CENT extension: Rationale for using N-of-1
approach
Example: ‘‘Past trials have compared the INR variability
of Coumadin with that of generic Barr-warfarin (Barr Lab-
oratories, Pomona, NY) in the US. These clinical studies
concluded that the 2 products were interchangeable,
although each study assessed INR variation as averaged
within groups rather than within individual patients. As of
May 2, 2005, no published studies have satisfied all rele-
vant interchangeability concerns: patients as subjects, com-
parison of variability within and between individuals, and
using INR as the outcome. Finding an appropriate design
for such a study has been an issue. However, the N-of-1
randomised, crossover study design is useful in making
treatment decisions at the individual and group level with
small sample sizes. ’’ [33].
Explanation:
It may not be immediately apparent to readers why an
N-of-1 trial, rather than a traditional RCT design, was used
to study a particular condition, intervention, outcome, or
combination of these. Certain patient populations (such as
those with rare diseases, pediatric populations) or sub-
populations (such as patients with comorbid conditions or
those using concurrent therapies) are often overlooked or
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often attempt to limit heterogeneity of the population under
study since evaluation of homogenous populations
increases the chances of detecting a signal (treatment
effect) among the noise (heterogeneity) [5]. Therefore,
RCT findings may not always be helpful for guiding the
treatment approach for a particular patient.
Reasons why an N-of-1 trial is the most appropriate
design for evaluation of treatment in a particular patient
or set of patients should be stated in the introduction of
the N-of-1 trial report. For instance, some conditions better
lend themselves to evaluation through N-of-1 design than
others. Guyatt et al. proposed guidelines for determining
when an N-of-1 trial may be appropriate (Box 3) [18]. It
is helpful to report whether these criteria were considered
in the decision to carry out the N-of-1 trial(s).
Item 2b
Standard CONSORT item: Specific objectives or
hypotheses
CENT extension: No change from CONSORT item 2b.
Example: ‘‘To describe the use of an N-of-1 randomised
clinical trial (N-of-1 RCT) in general practice as illustrated
by the case of a 16 year old boy with a learning and atten-
tion problem whose parents were convinced that amphet-
amines were necessary.’’ [34].
Example: ‘‘Our objectiveswere [1] to determinewhether in
children undergoing doxorubicin-containing chemotherapy,
topical vitamin E decreases an objective measurement of oralBox 3 Guidelines for choosing an N-of-1 trial
(reproduced from The Users’ Guides to the
Medical Literature [9])
Is an N-of-1 trial indicated for this patient?
Is the safety or effectiveness of treatment in doubt?
If effective, will the treatment be continued long
term?
Is an N-of-1 trial feasible in this patient?
Is the patient eager to collaborate in the designing
and carrying out of an N-of-1 trial?
Does the treatment have rapid onset and termination
of action?
Is optimal duration of treatment feasible?
Are targets of treatment that are important to the pa-
tient also amenable to measurement?
Can you identify the criteria to end the N-of-1 trial?
Is there a pharmacist who can help?
Are strategies in place for the interpretation of the
data?mucositis compared to placebo and [2] to assess the feasibility
of an innovative trial design of combining N-of-1 trials using
Bayesian meta-analysis.’’ [35].
Explanation: Same as CONSORT 2010 item 2b.11. Methods
11.1. Trial design
Item 3a
Standard CONSORT item: Description of trial design
(such as parallel, factorial) including allocation ratio
CENTextension: Describe trial design, planned number
of periods, and duration of each period (including run-in
and washout periods, if applicable)
Example: ‘‘Treatment was administered in 3 pairs, each
consisting of 2 periods in which either tramadol 50 mg BID
or placebo was administered for 6 days, followed by a
2-day washout period, and then the administration of the
alternate for 6 days. A 2-day washout period was also
carried out after pairs 1 and 2.’’ [36].
In addition for series: Whether and how the design was
individualised to each participant, and explanation of the
series design.
Example: ‘‘We considered awash out period of 1week suf-
ficient, given the short half life of the NSAIDs used in our
study. Previous n of 1 series and RCTs comparing NSAIDs
with paracetamol have used a similar wash out period.’’ [37].
Example: ‘‘Each subject underwent an n-of-1 trial. Visit
1 was followed by a 2-week run in phase to familiarize par-
ticipants with the protocol.’’ [38].
Note: No example of good reporting demonstrating indi-
vidualisation could be identified.
Explanation:
A succinct description of the intended trial design,
including number of periods and whether run-in or washout
periods were planned, will contribute to the readers’ interpre-
tation of the trial. Reporting of specific aspects of trial design
is addressed by items 3b through to 13 of the CENT checklist.
A run-in period occurs before a trial begins and is typi-
cally used to initiate trial medications (for example, to get
to a stable therapeutic dose), determine tolerability, assess
potential compliance with study regimens, or to allow for
wash-out of medication effects a participant was taking
before enrollment in the trial [39].
A washout period may occur between treatments to
allow the effects of one treatment to wear off before pro-
ceeding with the next (that is, to reduce carryover effect;
see CENT item 12c) or it may be used as a trial period in
itself in order to allow the effects of the preceding treatment
to fade or dissipate (that is, reversal design). A washout
may also be incorporated as a part of a treatment. Authors
should say which of these roles washout periods are
intended to play in the trial design.
Whether run-in or washout periods are employed, it is
helpful to give the rationale for their use, and their length
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ping blood thinning medication for patients’ blood coagula-
tion to return to its previous state).
For a series of N-of-1 trials, authors should report any
details of trial design (such as period length) that were
tailored around a particular participant, describing the indi-
vidualisations made.
Item 3b
Standard CONSORT item: Important changes to
methods after trial commencement, with reasons
CENT extension: No change
Example: ‘‘Sincewewere in the process ofmodel develop-
ment, the design was modified three times during the study.
From pilot II and throughout the study the cimetidine dose
was increased to 800 mg, and the patients were asked to regis-
ter the total duration of their trial. During pilot II the patients
were requested to record separate measures for pain, heart-
burn/acid regurgitations, andglobal symptoms.Themaximum
number of doses per day was reduced to two.’’ [40].
Explanation: This item is separate from the notion of
intentional changes due to individualisation of trial design
(item 3a). It is not possible to predict all possible circum-
stances in which changes to trial design/methods may be
made and whether such changes are warranted. Documen-
tation of any changes that occurred over the course of a trial
is encouraged (item 3b). Since N-of-1 trial protocols have
previously not been widely available, documenting changes
to the trial design is especially important.
Changes to the sequence of periods in a trial occur for
different reasons, such as tolerability of treatment, dose in-
terruptions, or even purposeful modification of the order of
treatments by participants or physicians. Authors should
document any changes that were made, with reasons; this
will enable readers’ assessment of potential bias in reported
findings.11.2. Participant(s)
Item 4a
Standard CONSORT item: Eligibility criteria for
participants
CENT extension: Diagnosis/disorder, diagnostic
criteria, comorbid conditions, and concurrent therapies
Example: ‘‘The participant was a 71-year-old male with
the primary diagnosis of dementia of the Alzheimer type. A
seizure disorder and a history of congestive heart failure
were also present. Medications, excluding study drugs,
were Dilantin 300 mg QD, Digoxin 0.25 mg QD, and Milk
of Magnesia 30 cc QD on odd days. Haloperidol 1 mg PRN
was chosen by the ward physician as back-up for behavioral
problems. Haloperidol 1 mg was given on six occasions, all
of which were more than 36 hours preceding saliva collec-
tion.’’ [41].
For series: same as standard CONSORT item.
Example: ‘‘There were 43 subjects recruited from respi-
ratory clinics primarily dealing with asthma and COPD inhospital and private practice settings. Inclusion criteria
required that subjects were aged between 40 and 80 years,
were current smokers or ex-smokers, experienced at least
mild shortness of breath on exertion, had a baseline FEV,
of !60% of predicted value and FEV1/forced vital capac-
ity (FVC) ratio!60%, were stable at time of entry into the
study (no deteriorations requiring emergency hospital or
local medical officer visits or hospital admissions in the
previous 28 days), and had poorly reversible airways
obstruction defined by the British Thoracic Society (an in-
crease in FEV, of not greater than 15% and 200 mL after
salbutamoll’). No attempt was made in our recruitment to
distinguish between emphysema and chronic bronchitis.
Patients were excluded from entry into the trial if they
had a history of asthma by their clinician, unstable airways
disease, other respiratory disease, other uncontrolled dis-
ease, had changes in their medication in the previous
28 days, or were on beta blocker medication.’’ [38].
Explanation: Since it is rare, in individual trials, for
eligibility criteria to be applied, a description of the condi-
tion(s) under study should be reported, authors should
describe patient characteristics such as the diagnosis, co-
morbid conditions, and concurrent medications, if relevant.
Providing this information will help readers gauge to which
populations and subpopulations the findings of trial are
applicable. For series of N-of-1 trials, authors should report
all of aforementioned details along with specific reasons
participants were not eligible for inclusion in the series
(that is, exclusion criteria), if applicable.
Item 4b
Standard CONSORT item: Settings and locations where
the data were collected
CENT extension: No change
Example: ‘‘individuals with insomnia were recruited by
three suburban Brisbane general practices, and from the
community directly, through regional Queensland news-
paper and television media campaigns.’’ [42].
Explanation: See CONSORT 2010 item 4b.
Item 4c
Standard CONSORT item: None (new for CENT)
CENT extension: Whether the trial(s) represents a
research study and, if so, whether institutional ethics
approval was obtained
Example: ‘‘The study was approved by the institutional
Research Ethics Board. Each child for whom parental con-
sent was obtained was enrolled in an N-of-1 trial.’’ [43].
Explanation: It has been suggested that an N-of-1 trial
undertaken solely to better manage an individual’s treat-
ment and that meets clinical ethical standards might be
considered a clinical investigation rather than research
and so may not require institutional review board oversight
[44,45]. The number of N-of-1 trials undertaken for clinical
investigation is unknown since accounts of such trials are
typically not published [46]. However, investigations
around a prospectively designed series of N-of-1 trials
intended for comparison or combination in meta-analyses
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should indicate this in the study report. If an N-of-1 trial
was carried out under the auspices of research [44] authors
should clearly state whether a health research ethics board
reviewed and approved the research study and whether
patient consent was obtained [47].
Interventions: Item 5
Standard CONSORT item: The interventions for each
group with sufficient details to allow replication, including
how and when they were actually administered
CENT extension: The interventions for each period with
sufficient details to allow replication, including how and
when they were actually administered
Example: ‘‘A double-blind, randomised, controlled
multi-crossover trial consisting of 12 test doses, six with
400 mg cimetidine and six with placebo, was conducted
in each patient. To ensure a spread of the cimetidine doses,
the test doses were ordered in six pairs, each containing one
dose of cimetidine and one dose of placebo. The sequence
within each pair was randomised. The patient was in-
structed to take one test dose when in need of symptomatic
relief and to measure its effect within 3-6 h. The patient
was also advised to avoid concurrent intake of other allevi-
ating agents or food before the symptomatic effect was
measured. A maximum of three doses were allowed per
day, with at least 6 h interposed between the doses.’’ [40].
Explanation: A distinguishing feature of N-of-1 trials is
that the intervention(s) can generally be tailored to meet a
patient’s unique profile [48]. Authors should provide the
name and content of the intervention(s) as well as the pro-
cedures for delivering the treatment(s). We recommend that
trial authors consult the TIDieR (Template for Intervention
Description and Replication) checklist for a listing of inter-
vention details that authors should include in their reports
[49]. In addition, authors may find the CONSORT
extensions for herbal [50,51], acupuncture [52], or
non-pharmacological [53,54] interventions helpful, if
applicable.11.3. Outcomes
Item 6a
Standard CONSORT item: Completely defined pre-
specified primary and secondary outcome measures,
including how and when they were assessed
CENT extension: Replaced by item 6a.1 and 6a.2
Item 6a.1
CENT extension: No change from CONSORT item 6a
Example: ‘‘Emetic episodes were recorded by a parent
in a study diary. The frequency of emetic episodes was
classified by absolute numbers, and categorized into com-
plete response (0 episodes/day), major response (1-2 epi-
sodes/day), or failure (O2 episodes/day). The primary
outcome was a comparison of the proportion of days in
each cycle that patients had a complete response when
treated with metopimazine vs. placebo. This outcome wasevaluated for a complete cycle of chemotherapy as well
as separately for the acute and delayed phases. Secondary
outcomes included the absolute number of emetic episodes
per day, ‘patient distress’ as assessed by a parent twice
daily (at noon and 8 p.m.) using a 6-face ‘happy face’ scale
ranging from 0 (no distress) to 5 (extreme distress) and the
frequency of adverse effects experienced during the treat-
ment and placebo cycles.’’ [43].
Example: ‘‘The outcome measures chosen were those
which the patient thought were most important, and included
well-being; nausea; vomiting; fever; abdominal gas and
pain; stool volume, consistency, and odor; and presence of
blood in the stool. Throughout the study, the patient kept a
diary in which these items were evaluated daily. 10 cm vi-
sual analogue scales were used to estimate well-being,
nausea, abdominal pain, and gas. Fever, vomiting, and the
presence of blood were assessed by means of yes/no
response. Stool consistency and odor were measured with
a two-point scale (normal/watery for consistency; normal/
foul for odor). Stool volume was measured in liters.
Because the patient found stool collection unpleasant, stool
volume was recorded only during the second week of each
treatment period.’’ [55].
Explanation:
All outcomes measured, whether primary or secondary,
should be identified and completely defined. It is well docu-
mented that RCTs are selectively reported; for instance,
40-62% of reports of RCTs report a different primary
outcome than their protocol [56]. In addition, where out-
comes are assessed at more than one time point, the
frequency of measurements should be indicated and authors
should state if one time point was of primary interest.
Because they are designed around an individual patient,
N-of-1 trials allow for collaboration between patients and
practitioners. Patients are often involved in this process to
help ensure that outcomes important for patients are
included [57e61]. In these instances, it is desirable for au-
thors to indicate who selected the outcomes.
Item 6a.2
CENT extension: Description and measurement proper-
ties (validity and reliability) of outcome assessment tools
Example: ‘‘The Body Image Avoidance Questionnaire
(BIAQ) developed by Rosen, Srebnik, Saltzberg and Wendt
(1991) was used to pretest and post-test body image distur-
bance. This scale is designed to measure behaviors that
often accompany body image disturbance. The BIAQ con-
tains 19-items that deal with ‘avoidance of situations that
provoke concern about physical appearance’ (Fischer &
Corcoran, 1994). Totaling the scores on each of the six
point items scores the questionnaire. The possible range
is 0-94. The higher the score the more avoidance behaviors
are used. The internal consistency for the BIAQ is,excel-
lent, with a Cronbach’s alpha of .89. It has a
stable 2 week, test-retest reliability coefficient of .87.
Further, the BIAQ has fair to good concurrent validity, with
a low but significant correlation of .22 with body size
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Questionnaire. It also has good known-groups validity,
significantly distinguishing between clinical (bulimia nerv-
osa) and nonclinical populations and has been shown to be
sensitive to changes in clients with body-image disturbance
(Fischer & Corcoran, 1994).’’ [62].
Explanation: The instrument used to measure primary and
secondary outcomes often lack evidence of reliability and val-
idity [63]. Providing explicit details about the measurement
properties of such tools will enable readers to gauge whether
outcomes were measured in a sufficiently robust manner (for
example, sensitive to change, valid for the condition under
study), and thus the trustworthiness of findings [64]. In a
review of 138 RCTs of pediatric acute diarrheal diseases,
87 (63%) studies explicitly stated one or more primary out-
comes; none reported the use of a valid and reliable primary
measure or instrument to evaluate the primary outcome [63].
Similarly, 2194 different instruments have been used in 10
000 trials in schizophrenia, of which 1142 had only been used
once [65]. In another study, of non-pharmacological trials,
one third of the claims of treatment superiority based on
unpublished scales would not have been made if a published
scale had been used [66]. In the absence of empirical evidence
of the reliability and validity of outcome measures, readers
should be skeptical about whether reported effect estimates
reflect the intended concept and whether they are relevant
or appropriate in practice.
Item 6b
Standard CONSORT item: Any changes to outcomes af-
ter the trial commenced, with reasons
CENT extension: No change
Example: No example of good reporting could be
identified.
Explanation: Selective outcome reporting in clinical tri-
als has been extensively documented [56], and similar evi-
dence is emerging for systematic reviews [67]. In most
cases, changes to planned outcomes have been shown to
be associated with the nature and direction of findings, re-
sulting in a bias of the evidence base toward favourable ef-
fect estimatesda concept termed outcome reporting bias. It
is unlikely that selective outcome reporting is limited to just
parallel group trials and reviews. Until the registration of
N-of-1 trials is standard practice (see CENT item 23) it will
remain difficult for readers to detect selective reporting in
N-of-1 trial reports. Trial authors should indicate whether
changes to outcomes were made (for example, added,
removed, re-prioritised) and their rationale for doing so.11.4. Sample size
Item 7a
Standard CONSORT item: How sample size was
determined
CENT Extension: No change
Example: ‘‘Estimation of the needed number of cross-
overs (that is, ‘sample size’) was based on having at least80% power (b 5 0.20) to detect a 50% reduction in symp-
toms, with significance testing at the a 5 0.05 level. Vari-
ability in the Conners ratings was estimated based on
normative data in school-aged children, which show stan-
dard deviation (SD) of 5.2 (Werry et al., 1975). Based on
the baseline Conners scores of 17 and 15 in the two chil-
dren, a 50% reduction in symptoms could be detected with
three cross-overs, under the given model parameters. We
felt that the number of cross-overs should ideally be higher,
to allow for the possibility of higher intra-individual vari-
ability, and selected a target of five cross-overs.’’ [68].
Example: ‘‘For a conventional RCT, the sample size
required to detect a difference in effect of 8 on the
FACIT-F fatigue subscale between MPH and placebo with
5% significance level and 80% power, using a two-sided
test, is 33 per treatment group. Allowing for 30% attrition
raises the sample required to 47 per group or 94 overall.
Using the same information, assuming no period effect or
treatment  time interaction, computer simulation of size
N 5 10,000 in SAS (SAS Institute Inc., Cary, NC, USA)
was used to model the required sample size for the equiv-
alent aggregated n-of-1 design. If 60% of recruited patients
complete the first cycle, 50% complete the first two cycles,
and 45% complete all three cycles, then 21 patients would
be needed to satisfy the same significance and power
requirements.’’ [69].
Explanation:
Sample size is a distinct concept inN-of-1 trials.Within an
individual trial, sample size may refer to a calculation around
the number of periods comprising an individual trial or the
number of measurements within a treatment period, if done.
Within a series of trials, sample sizemay also refer to a calcu-
lation of the number of individual trials comprising the series,
as indicated by the two above examples.
In a series of trials, the number of repetitions of periods
across individual N-of-1 trials, and repeated sampling
within periods, may be more important than the number
of individual trials carried out in the series [69]. As such,
whether a sample size was determined for any of these
should be reported. For individual trials, the method for
determining the planned number of measurements within
each period or the number of periods within a trial should
be reported. It is unlikely that a valid sample size for the
number of periods can be calculated for trials with less than
three crossovers, since the degrees of freedom for such a
test would be quite small. In these instances, investigators
should report the posterior probability or odds that one
treatment is better than the other.
For series of N-of-1 trials, investigators who calculated a
sample size should report how the intended sample size was
calculated in the same manner as is done and reported in
parallel group RCTs. The rationale and source of variables
used to compute a sample size should be stated. For
instance, if the minimum detectable difference between
two treatments was obtained from group trial data, this
should be stated. In addition, Type I error (that is, the
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and power (that is, the probability of rejecting the null
hypothesis when it is false) as well as whether the test is
one sided or two sided should be stated.
Item 7b
Standard CONSORT item: When applicable, explana-
tion of any interim analyses and stopping guidelines
CENT extension: No change
Example: ‘‘Patients had the optionofprematurely terminat-
ing a study period if they believed theywere receiving placebo
and wanted to switch to the next treatment period.’’ [32].
Example: ‘‘We did not plan to stop the evaluation early.’’
[70].
Explanation:
Early stopping in N-of-1 trials refers to intentional stop-
ping within a trial period based on a priori stopping rules.
Such rules may be planned in anticipation for minor
adverse effects or potential ineffectiveness of an interven-
tion. Early stopping is distinct from participant withdrawal
(or dropping out) from the trial completely as well as from
investigator-determined exclusion. Withdrawal implies un-
planned stopping of a trial, which, as in parallel group tri-
als, may be due to a number of unanticipated reasons (such
as serious adverse events).
When early stopping of a period within an N-of-1 trial
occurs, the participant remains enrolled and continues on
to subsequent periods. Potential reasons for early stopping
include adverse effects or perceived lack of efficacy. In
such circumstances, a participant may contact the clinician
about how she or he is feeling and, after documentation,
proceed to the next period in the a priori planned sequence;
early stopping can be achieved without interfering with ran-
domisation or blinding. The pre-specified reasons for stop-
ping a period early should be reported.
Early stopping in N-of-1 trials (that is, selective early
discontinuation of a single period) is different than early stop-
ping inRCTs,which results in the discontinuation of the entire
trial. Parallel group RCTs may be stopped early because of
demonstrated treatment benefit or harm seen at interim ana-
lyses. Such trials are problematic because they tend to prema-
turely promote new drugs based on ‘‘random highs’’ (or lows)
in treatment effect [71] andmaymisestimate treatment effects
for the outcome precipitating the early stopping [72,73].
Any a priori rules for interim analyses and early stopping,
andhow theseweredetermined, shouldbe stated.Consideration
of howearly stoppingwill affect the analysis of the trial or series
should be described, particularly in longitudinal analyses11.5. Randomisation: sequence generation
Item 8a
Standard CONSORT item: Methods used to generate
the random allocation sequence
CENT extension: Whether the order of treatment
periods was randomised, with rationale, and method used
to generate allocation sequenceExample (randomised): ‘‘The order of medication pe-
riods was randomly assigned within each of 3 pairs of
periods, according to a computer-generated randomisation
schedule.’’ [74].
Example (non-randomised): ‘‘The specific treatment
approach used was alternated each week so that two ses-
sions of one treatment were followed by two sessions of
the other during the ensuing week. The two-session alter-
nating approach was utilized to ensure that neither treat-
ment was given an advantage in terms of the number of
days between treatment and mastery probes administered
in the following session.’’ [75].
Explanation:
In traditional, parallel group RCTs, randomisation (that
is, the chance based process of assigning participants to
treatment or control condition) is used to ensure the even
distribution of participant characteristics between groups.
In N-of-1 trials, as in crossover group RCTs, the potential
for confounding by covariates is eliminated due to the nature
of the designdparticipants act as their own control. Howev-
er, the assignment of treatment periods is still an important
methodological consideration in N-of-1 trials, which may be
done with or without employing randomisation.
In N-of-1 trials, randomisation for a patient refers to the
random assignment of a treatment period to a specific treat-
ment within a pair or block of periods of a pre-specified
size. It is typically used to ensure that each treatment has
an equal chance of being administered and so that patients
or their health professionals cannot predict the next treat-
ment (that is, to preserve blinding). This works well when
many randomised treatment blocks are carried out or when
there are a large number of patients in a series. Randomisa-
tion may be used to select the starting treatment, as done in
group RCTs.
However, relying solely on randomisation is sometimes
problematic, such as when an outcome unknowingly, pro-
gressively deteriorates or improves. As described by the
N-of-1 panel of the Agency for Healthcare Research and
Quality’s DEcIDE (Developing Evidence to Inform Deci-
sions about Effectiveness) group, an alternative to random-
isation is the use of counterbalancing to select the order of
treatments [76]. Many N-of-1 trials employ a standard, two
treatment design (that is, treatment pair), which, when
randomised, consistently places either A or B in the latter
position 50% of the time (that is, ABAB or BABA for a
4 period sequence with block size of 2). If there is progres-
sive deterioration (or improvement), the later treatment will
on average result in worse (or better) outcomes than the
treatment preceding it. While an N-of-1 design is recom-
mended to be used only for stable conditions rather than
progressive conditions (see box 3), it may sometimes be
the only feasible mechanism of evaluation when an
informed treatment decision is needed, or may be used to
evaluate conditions or outcomes that are not necessarily
known to be progressive. In these situations, a researcher
may choose to make use of a balanced-counterbalanced
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order (such as AB or BA) is systematically alternated (that
is, ABBA or BAAB) so that neither treatment suffers a
worse fate than the other, solely based on the ordering
within a treatment block. Whether randomisation, counter-
balancing, or another mechanism was used to determine the
order of treatments should be described by authors, along
with a rationale and how it was achieved.
As in group RCTs, the method used to decide on the
treatment sequence is an essential method in N-of-1 trials.
Whether or not randomisation was used should be reported
along with the rationale for the selected treatment order
with special attention for how the effect of time (that is,
period effect) was addressed. The mechanism used to
generate the randomisation sequence, such as computer-
generated, random numbers table, coin toss or other
random selection process, should be described in enough
detail to enable readers to gauge whether the method used
was robust. Simply stating that randomisation was used is
not sufficient. Additionally, authors should describe other
details of randomisation, as they apply (see CENT item 8b).
Item 8b
Standard CONSORT item: Type of randomisation;
details of any restriction (such as blocking and block size)
CENT extension: When applicable, type of randomisa-
tion; details of any restrictions (such as pairs, blocking)
Example: ‘‘Following a 2-week run-in period, quinine
sulfate and matched placebo capsules were compared in
three 4-week treatment blocks (each block consisting of
2 weeks active drug and 2 weeks placebo in random or-
der).’’ [77].
Explanation:
If randomisation was used to generate treatment
sequence, the unit of randomisation, such as within a pair
or block, or if treatments were simply alternated after
randomly assigning the starting treatment, should be re-
ported [78]. If blocking was used, the block size should
be reported as well as whether the size was fixed or
randomly decided. As with parallel group RCTs, if the tria-
lists became aware of the block size(s) during the trial, that
information should be reported as such knowledge could
lead to code breaking [27]. Whether a predetermined ratio
other than 1:1 was used should also be reported, along with
a rationale for the type of randomisation used and any asso-
ciated limitations.
Item 8c
Standard CONSORT item: None (new for CENT)
CENT extension: Full intended sequence of periods
Example: ‘‘Within each pair, the sequence was random-
ized by the pharmacist who had no contact with the patient.
The actual sequence was [drug, placebo], [drug, placebo],
[placebo, drug]. ’’ [79].
Explanation: In existing N-of-1 trial reports, it is com-
mon practice to state the sequence completed in the trial
in the results section. However, the generation of a treat-
ment sequence is a method carried out before the start ofthe trial and so should be reported in the methods section
of a trial report, even if it changed after the start of the trial.
The completed sequence and reasons for changes, if any,
should be reported as per CENT item 14a (numbers and
periods analysed). This guidance is in line with CONSORT
and other reporting guidance
For series of N-of-1 trials, where the sequence is
different for each individual trial, it may not be possible
to report the planned sequence for each trial in the text.
Sequences for each individual trial may instead be included
as an appendix.
11.6. Randomisation: allocation concealment
mechanism
Item 9
Standard CONSORT item: Mechanism used to
implement the allocation sequence (such as sequentially
numbered containers), describing any steps taken to
conceal the sequence until interventions were assigned
CENT extension: No change
Example: ‘‘Active and placebo medication was issued in
‘Webster packs’ manufactured by Webstercare (packed and
sealed medication according to individual’s dosage require-
ments, such as by time of day, day of the week and week
number) by a local pharmacist not participating in the trials
in accord with the randomisation schedule supplied by the
database manager. Patients, participating GPs and research
staff were blinded to all randomisation and packaging pro-
cedures until completion of each trial.’’ [42].
Explanation: See CONSORT 2010 item 9.
11.7. Randomisation: sequence implementation
Item 10
Standard CONSORT item: Who generated allocation
sequence, who enrolled participant, and who assigned
participant to interventions
CENT extension: No change
Example: ‘‘The randomisation code for eformoterol and
placebo turbuhalers was independently supplied in opaque
envelopes, with allocation on study entry in order to blind
subjects, research staff, and two respiratory physicians
who inspected the outcome data for each individual partic-
ipant.’’ [38].
Explanation: See CONSORT 2010 item 10.
11.8. Blinding
Item 11a
Standard CONSORT item: If done, who was blinded af-
ter assignment to interventions (for example, participant,
care providers, those assessing outcomes) and how
CENT extension: No change
Example: ‘‘Both the patients and the researcher interacting
with them and conducting the analyses were blinded to when
patients were taking the active drug or the placebo.’’ [77].
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Item 11b
Standard CONSORT item: if relevant, description of the
similarity of interventions
CENT extension: No change
Example: ‘‘Placeboswere identical in appearance, texture
and weight to the corresponding active medication and con-
tained 3% active valerian to ensure identical odor.’’ [42].
Explanation: See CONSORT 2010 item 11b.11.9. Statistical methods
Item 12a
Standard CONSORT Item: Satistical methods used to
compare groups for primary and secondary outcomes
CENT extension: Methods used to compare data be-
tween interventions for primary and secondary outcomes
Example: ‘‘An N-of-1 RCTwas considered positive if the
CRQ dyspnea scorewas higher (i.e., less dyspnea) during the
oxygen treatment period in all three pairs and if the difference
between oxygen and placebo periods was 0.5 or greater dur-
ing at least two of the three pairs. Analysis of each N-of-1
RCT included a paired t test. Mean oxygen and placebo
gas usagewas determined by averaging the amount used over
each of the periods for each patient.’’ [32].
Explanation:
In line with recommendations made by the International
Committee for Medical Journal Editors (ICMJE) and the
CONSORT group, analytical methods should be described
‘‘with enough detail to enable a knowledgeable reader with
access to the original data to verify the reported results.’’
[80] Two broad analytic approaches are used in N-of-1 tri-
als: visual assessment and statistical analysis. Many N-of-1
trials authors provide a visual representation of the data, al-
lowing readers to inspect the slope, variability, and patterns
of the data, potential treatment overlap between periods,
and the overall reliability and consistency of treatment ef-
fects [81,82]. Analytical aids such as a line of best fit
may sometimes be used to facilitate interpretation of visu-
ally presented data. If done, authors should describe how
the analysis was carried out.
With the increasing focus on evidence based medicine,
some argue that the statistical determination of effect sizes
(magnitude and direction) provides trial findings in manner
that can be used more easily understood and used in clinical
decision making and by future researchers (that is, for meta-
analysis) [82]. It is not usual for visual assessment to precede
and inform the need for statistical analysis, based on an im-
plicit rule (that is, if one treatment seems to yield better out-
comes than another most of the time). Another rule may be
based on the number of data points, since, as more data are
displayed on a graph (such as multiple measurements per
period), visual assessment becomes more difficult unless
there is very little within-sample variation.
In N-of-1 trials special consideration of the handling and
summarising of data is required since data are typicallypresented for each outcome, in addition to estimation of
treatment effect. Authors may or may not choose to statis-
tically summarise individual trial data. If done, several op-
tions are available and authors should state which data were
summarised and how this was done. For instance, authors
may plan to summarise multiple measurements of a given
outcome within a period (that is, length of time when only
one treatment is given) or measurements from all periods of
a recurring treatment overall (that is, combined data from
all periods of a given treatment). If data are combined,
methods for summarising (such as the mean) and esti-
mating their variance (such as standard deviation) should
be reported. Whether a visual or statistical approach to
analysis (or both) was used (and a description of how each
method was carried out, as specified above) should be
reported. If rules were used to determine the need for statis-
tical analysis, authors are encouraged to report what the
rule(s) is and whether it was specified before seeing the
data (a priori).
A number of statistical approaches for determining treat-
ment effect sizes have been documented in N-of-1 trials
with little consensus [83e85]. Authors should describe
the selected measure used to generate effect estimates, that
is, to compare data between treatments (such as mean dif-
ference), and which measure will be used to indicate the
precision (uncertainty) of the estimate [32,86,87]. As in
group trials, a 95% confidence interval is standard, but
occasionally other levels are used depending on the level
of conservativeness needed. Many biomedical journals
require or strongly encourage the use of confidence inter-
vals [80]. They are especially valuable in relation to differ-
ences that do not meet conventional statistical significance,
for which they often indicate that the result does not rule
out an important clinical difference. The use of confidence
intervals has increased markedly in recent years, although
not in all medical specialties [86]. Although P values
may be provided in addition to confidence intervals, results
should not be reported solely as P values [88]. If authors
choose to also report P values, the actual value (such as
P 5 0.003) should be given, rather than whether it is above
or below an arbitrarily chosen point (such as P ! 0.05).
If both continuous and dichotomous or categorical out-
comes are measured, authors should distinguish their
approaches for analysing each type of data. For reports
combining data from a series of N-of-1 trials, refer to
CENT item 12b.
If sensitivity analyses were planned and carried out,
authors should state what analyses were done (that is,
excluding outlying data points, periods stopped early, etc.).
Item 12b
Standard CONSORT item: Methods for additional ana-
lyses, such as subgroup analyses and adjusted analyses
CENT extension for series only: If done, methods of
quantitative synthesis of individual trial data, including
subgroup analyses, adjusted analyses, and how heterogene-
ity between participants was assessed (for specific guidance
Box 4 Considerations of crossover designs
Period effectdA change that would have occurred
even in the absence of treatment, due to time [96].
Carryover effectdThe persistence, into a later period
of treatment, of some of the effects of a treatment
applied in an earlier period [97].
Intra-subject correlationdThe variation, exhibited
by a single person, on repeated measurements. As
an illustrative example, observed resting pulse rate
will show considerable minute-to-minute variation
but little evidence of any trend over time. Successive
within-subject values are unlikely to be independent
[98].
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PRISMA Statement)
Example: ‘‘Bayesian analyses combining N-of-1 trials
employed a 2-level random effects model to describe the
posterior distributions of treatment effectiveness. For these
analyses we assumed a common within-patient variance.
More complex variance structures did not improve model
performance. Analyses used both non-informative and,
separately, informative priors derived from published trial
results.’’ [89].
Example: ‘‘To address the effect of oxygen on the entire
group, we conducted repeated-measures analysis of vari-
ance, examining the effects of treatment, pair, and the
treatment-pair interaction. Mean oxygen and placebo gas
usage was determined by averaging the amount used over
each of the periods for each patient. The correlation
between mean oxygen and mean placebo gas usage was
calculated for the entire group as an intraclass correlation
coefficient (ICC).’’ [32].
Explanation:This item is only applicable for reports of se-
ries of N-of-1 trials, where authors carried out a quantitative
synthesis of data frommore than one trial. Doing somay pro-
vide readers with both an overall average effect, potentially
stratified by participant or study characteristics, and revised
estimates of each individual’s outcomes that are informed
by the results of other participants [8]. If subgroup analyses
were performed, for instance, stratification by participant
or study characteristics, this should be explicitly stated.
There is not yet a single, widely recognised approach
to synthesising data from N-of-1 trials, but it should be
noted that methods are likely distinct from the synthesis of
group trial data. Meta-analytic methods for combining
individual trials have been explored and reported by
some [8,46,90,91], but further exploration is needed.Authors
should report the approach used (such as Bayesian or fre-
quentist) and the models used (such as fixed or random
effects). In addition, the summary measures used and the
level at which the resulting effect estimate would be consid-
ered significant (such as 95% confidence interval) should be
reported. Since the number of observations taken in each N-
of-1 study is relatively small, and results may vary substan-
tially between individuals, the explicit statistical method
used to explore relative heterogeneity both within and be-
tween individuals should be reported [46]. In some instances,
subgroup and sensitivity analyses may be used to explain dif-
ferences between treatments among individuals in a series.
Authors should be clear about whether raw data or
summary data from individual trials were used to determine
group estimates. In line with individual patient data
meta-analyses [92], raw data is preferable. Specific reporting
guidance for systematic reviews (and retrospective meta-
analyses) that include N-of-1 trials and series is planned.
However, in the interim, authors are encouraged to refer to
the PRISMA (Preferred Reporting Items for Systematic
reviews andMeta-Analysis) Statement [93,94], as the overall
review process and approach to reporting it will be similar.Item 12c
Standard CONSORT item: None (new for CENT)
CENT extension: Satistical methods used to account for
carryover effect, period effects, and intra-subject correlation
Example: ‘‘the averages of these differences for the sub-
jects who began the alternating-treatment sequence with
amphetamine and for those who began with caffeine were
compared in a two-sample t-test crossover analysis as
described by Hills and Armitage and Armitage and Berry.
This method accounts for sequence effects in addition to
drug effects.’’ [95].
Example: ‘‘Carryover and time trend significance were
tested using random-effects regression models that included
treatment pattern variables and time together with a time-
by-treatment interaction term, respectively’’ [89].
Explanation:
A common issue for N-of-1 trials (a form of crossover
study) is whether the outcome in the current period is influ-
enced by the treatment given in the previous period. If the
effects of an intervention are long lasting, they may carry
over into the next period if the washout period for a given
treatment is insufficient or absent. This has the potential to
result in biased estimates of differences between interven-
tions. Authors should report whether a carryover effect
was explored and how it was accounted for in the analysis.
A period effect is a change that would have occurred even
in the absence of treatment, due to time; if examined,
methods of doing so should be reported [96]. See Box 4
for definitions of period effect, carryover effect, and intra-
subject correlation.
Authors should also be aware thatmultiple observations in
a single patient are not independent and that treating them as
‘‘independent’’ data is a serious problemwhich may result in
increased type I or type II error [99], as in group crossover
RCTs [100]. The method used to determine whether data
are autocorrelated (as in time series analysis) [101] as well
as the method(s) used to account for it (such as long baseline
and post-intervention data) [102] should be described.
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12.1. Participant flow (a flow diagram is strongly
recommended)
Item 13a
Standard CONSORT item: For each group, the numbers
of participants who were randomly assigned, received in-
tended treatment, and were analyzed for the primary
outcome
CENT extension: Replaced by item 13a.1 and 13a.2
Item 13a.1
CENT extension: Number and sequence of periods
completed and any changes from original plan, with reasons
Example: ‘‘The completed treatment order therefore
was: placebo, valproic acid, placebo, placebo, valproic
acid, placebo, missed, valproic acid.’’ [103].
Example: ‘‘The order in which treatments (d 5 drug,
p 5 placebo) were given was: p d d p d p p d p d.’’ [55].
Note: No example reporting changes from the original
plan could be identified.
Explanation: The number and order of treatments as
received by a patient may differ from what was determined
by randomisation or otherwise planned a priori. The actual
completed sequence may be represented in a trial pictorialFig. 5. Flow diagram from N(see CENT item 17a.1), but it is important that authors
distinguish whether changes were made to the original
plan, and why, so readers can judge whether changes are
justified or may be associated with bias, if, for instance,
the change was associated with a treatment effect.
Item 13a.2
CENT extension for series only: the number of partici-
pants who were enrolled, assigned to interventions, and
analyzed for the primary outcome
Example: Flow diagram (Fig. 5) from Nonoyama et al.
[32].
Explanation:
The phases for a series of N-of-1 trial are akin to those of a
parallel group RCT (such as recruitment, enrollment, treat-
ment allocation, follow-up, analysis). The design and conduct
of some N-of-1 trial series is straightforward, and the flow of
participants, particularly when there are no exclusions or los-
ses to follow-up (item 14c), through each phase of the study
can be described adequately in a few sentences. A diagram de-
picting the flow of participants through phases of an N-of-1
trial series (Fig. 4, CENT flow diagram) will provide a snap-
shot ofwhenandwhy participantswere excluded, andwhether
such exclusions are indicative of potential bias in treatment es-
timates, and will assist in gauging generalisability of findings.onoyama et al. [32].
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because of a treatment related harm relating to their partic-
ular condition are not necessarily representative of the
broader patient population. However, the number of people
assessed for eligibility but excluded (and reasons why) is a
useful indicator of whether inclusion criteria, and thus sub-
sequent findings, are appropriate or applicable to a real life
scenario.
Item 13b
Standard CONSORT item: For each group, losses and
exclusions after randomisation, together with reasons
CENT extension for series only: Losses or exclusions of
participants after treatment assignment, with reasons, and
period in which this occurred, if applicable
Example: ‘‘Complete results for 7 of the 8 study weeks
were obtained, because the patient was ill and away from
school on the Friday of the 7th week.’’ [103].
Example: ‘‘One patient withdrew halfway through the
final period-pair due to unrelated personal reasons. A sec-
ond patient was hospitalized for gastrointestinal bleeding
during the second period-pair, and warfarin treatment was
discontinued. For both patients, data collected during
their participation in the study were included in the anal-
ysis.’’ [33].
Example: ‘‘The study was terminated on day 5 of the last
placebo period because of epistaxis.’’ [104].
Explanation:
With respect to individual N-of-1 trials and series of trials,
exclusions and losses to follow-up may be incurred at two
levels. In a series of N-of-1 trials, a particular participant
may be excluded or lost to follow-up after treatment alloca-
tion (see item 13a.2). In the case of an individual trial, exclu-
sions or losses to followupmay occurwhen a participant fails
to complete a particular period or set of periods yet continues
on to complete the remainder of the trial as planned. In the
latter case, investigators may choose to analyse completed
pairs or blocks of treatment. If this is done, the periods
excluded from analysis should be reported.
In N-of-1 series, when data from participants who were
lost to follow-up are excluded from the analysis entirely,
erroneous conclusions can be reached. Knowing the num-
ber of participants who did not complete the trial and
whose data are not included in the analysis permits the
reader to assess to what extent the estimated efficacy of
therapy might be under or overestimated in comparison
with ideal circumstances. Intention-to-treat analysis is
fundamental to preserving the pre-planned statistical
power of research studies, any reduction in which may
cause treatment effects to go undetected or be wrongly
estimated.
Authors should also distinguish between exclusion of
participants based on predetermined or investigator-
determined criteria (such as ineligibility, withdrawal from
treatment, and poor adherence to the trial protocol) and
attrition resulting from loss to follow-up, which is often
unavoidable.12.2. Recruitment
Item 14a
Standard CONSORT item: Dates defining the periods of
recruitment and follow-up
CENT extension: No change
Example: ‘‘Between April and November 2001, [physi-
cians] were asked to select patients from their medical
records who met the following criteria. The study
comprised of a series of N-of-1 trials with a duration of
10 weeks.’’ [29].
Explanation: In an individual N-of-1 trial, purposeful
‘‘recruitment’’ generally does not happen; rather the deci-
sion to conduct an N-of-1 trial may stem from the need
to answer a clinical question based on uncertainty of treat-
ment effect for a particular individual. The concept of
recruitment is more applicable to series of N-of-1 trials
led by a broader, population-based question for which
RCT evidence is lacking or inapplicable. The period of
recruitment for a series of N-of-1 trials should be reported
as well as whether and how long a follow-up period lasted.
The start and end dates of the trial should be reported,
although authors should be mindful of the potential for
patient identification when combined with other personal
information (items 4a, 4b, and 15).
Item 14b
Standard CONSORT item: why the trial ended or was
stopped early
CENT extension: Whether any periods were stopped
early, and whether the trial was stopped early, with
reason(s)
Example: No example of good reporting was identified.
Explanation:
N-of-1 trials, may, like parallel group trials, end after their
pre-specified duration or end earlier than planned for a num-
ber of different reasons. The reporting of this item overlaps,
in parts, with item 14c. Specifically, losses and exclusions
during an individual N-of-1 trial essentially accounts for
some of the reasons that early stopping may occur. Data
may not always be lost and, when available, may be very
informative. For example, a participant may consistently
stop a period early in a blinded fashion due to deterioration
or adverse effect. Knowledge of such information will allow
readers to judge whether the early stopping of a period is
important and has any impact on the reported findings.
In other instances, reasons for early stopping may be
planned or anticipated (item 7b) and may or may not be
related to trial results. Interim analyses may reveal a benefit
or no difference between treatment alternatives (that is, fu-
tility) leading investigators to decide to end a trial early.
Timing of interim analysis, when the trial was stopped
(indicating the specific period), and reasons why should
be stated.
For the same reasons as in parallel group trials [72].
interim analyses should prudently employed, interpreted
with caution and explicitly reported as such. In N-of-1
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tions of treatment periods (that is, sample size), overesti-
mate treatment effect, or uncover spurious associations.12.3. Baseline data
Item 15
Standard CONSORT item: A table showing baseline
demographic and clinical characteristics for each group
CENT extension: No change (no table necessary for
individual trials)
Example: Table of baseline characteristics (Fig. 6) from
Smith et al. [38].
Explanation: Whether an individual or series of trials
was done, it is important to provide the reader with under-
lying demographic and clinical information for each partic-
ipant to aid in interpreting appropriate application of the
results. When reporting a series of N-of-1 trials, it may
not be feasible to present individual characteristics for each
patient, but a table with descriptive summary data for base-
line characteristics should be included. For small series
(n  10), authors should aim to provide characteristics
for each patient. The items of most interest include demo-
graphics, clinical history, socioeconomic data, prior medi-
cations taken, baseline health measurements, and any
other baseline characteristic specific to the trial at hand that
authors think may aid readers to gauge the generalisability
of the findings.Fig. 6. Table of baseline characteristics from Smith et al. [38].12.4. Numbers analysed
Item 16
Standard CONSORT item: For each group, number of
participants (denominator) included in each analysis and
whether the analysis was by original assigned groups
CENT extension: For each intervention, number of
periods analyzed
Example: No example of good reporting could be
identified.
In addition for series: If quantitative synthesis was
performed, number of trials included
Example: ‘‘For both patients, data collected during their
participation in the studywere included in the analysis.’’ [30].
Explanation:
Analysis according to the trial as planned (such as
intention-to-treat including data from all measurements or
periods) rather than as actually occurred (such as per proto-
col) has become standard practice in group RCTs. Authors
should report both the number of periods from which data
were analysed as well as how missing periods (or periods
during which outcomes were unavailable) were analysed.
Furthermore, as indicated in item 3a, authors should state
the planned number of periods to be included in analysis,
for each intervention, so readers can compare planned
versus actual and make their own judgments. Authors
should also state whether information for all outcomes isavailable for all periods, or specify which periods were
included in analysis for each outcome.
Intention-to-treat analysis allows data from all partici-
pants to factor into the analysis, regardless of the reason
for not following the protocol. However, since intention-
to-treat analysis can provide very conservative estimates
if data are missing, authors should explicitly describe and
rationalise any methods of imputation used.
For series of trials, if quantitative synthesis (such as
meta-analysis) is performed, the number of trials included
in the synthesis should be reported.
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Item 17a
Standard CONSORT item: For each primary and sec-
ondary outcome, results for each group, and the estimated
effect size and its precision (such as 95% confidence
interval)
CENT extension: Replaced by items 17a.1 and 17a.2
Item 17a.1
CENT extension: For each primary and secondary
outcome, results for each period; an accompanying figure
displaying the trial data is recommended
Example: Results (Fig. 7) from Estrada et al. [105].
Example: Results (Fig. 8) from Nonoyama et al. [32].
Explanation: Outcome data displayed in a figure or table
are often clearer than descriptions in text. A clear descrip-
tion of the results for each treatment in each pair or block
should be provided for each primary and secondary
outcome. For each outcome, if repeated measures within
a period are combined, a summary measure (such as mean
or median) and indication of variance (such as standard
deviation or interquartile range) should be reported.
One possible way of presenting individual patient data is
to plot all outcome measurements for each period over the
trial duration, as shown in the example from Estrada et al.
(Fig. 7) above and Fig. 3 (N-of-1 trial pictorial). Outcome
measurements are plotted on the Y-axis, units of time (days,
weeks, etc.) along the X-axis, and vertical lines or some
other distinction made between treatment periods and pairs
or treatment blocks. For a series of N-of-1 trials, authors
may wish to present individual trial pictorials in an
appendix. For individual and series of N-of-1 trials, a table
reporting each person’s complete raw data is strongly rec-
ommended (as an appendix if necessary), consistent with
the current open data movements [106,107].
Item 17a.2
CENT extension: For each primary and secondary
outcome, the estimated effect size and its precision (such
as 95% confidence interval)
Example: Individual trial data (Fig. 9) from Avins et al.
[108].Fig. 7. Results from Estrada et al. [105].Example: Individual trial data in a series (Fig. 10) from
Zucker et al. [89].
In addition for series: if quantitative synthesis was
performed, group estimates of effect and precision for each
primary and secondary outcome
Example: Series data (Fig. 11) from Nonoyama et al.
[32].
Example: Series data (Fig. 12) from Coxeter et al. [42].
Explanation:
When reporting on the treatment effect size, comparison
between a summary of all measures for each treatment (that
is, within and across periods) is typical. Effect size esti-
mates should be accompanied by a confidence interval.
For binary outcomes, the effect size may be represented
by a relative risk (risk ratio), odds ratio, or risk difference;
a mean difference is typically calculated for continuous
data. Authors should provide a confidence interval to indi-
cate the precision (uncertainty) of the estimate [86]. If P
values are reported, the actual value (such as P 5 0.003)
rather than whether it is above or below an arbitrarily cho-
sen point (such as P ! 0.05) should be provided.
For an individual trial, authors should report the effect
size and confidence interval for each outcome (Fig. 9).
For series of trials, authors may wish to report individual
trial effect sizes separately (Fig. 10) or pool data for each
outcome among series participants (Figs. 11 and 12). More
information on the methods for combining N-of-1 trial data
can be found in the Agency for Healthcare Research’s
user’s guide for N-of-1 trial design and implementation
[76]. When effect sizes are combined between trials, au-
thors should still report calculated effect sizes and precision
(such as 95% confidence interval).
Effect sizes should be reported for all planned primary
and secondary end points, and for all participants if a series
was carried out, not just statistically significant or inter-
esting effects. The selective reporting of outcomes within
population based RCTs is a widespread and serious prob-
lem (see CENT item 6a.1). As previously stated, although
we are unaware of empirical evidence of selective reporting
of data for only statistically significant or interesting out-
comes in N-of-1 trial reports, it is conceivable and authors
should avoid this practice.
Item 17b
StandardCONSORTitem:Forbinary outcomes, presenta-
tion of both absolute and relative effect sizes is recommended.
CENT extension: No change
Example: No example of good reporting identified.
Explanation: As in group crossover trials, the measure-
ment of binary outcomes in N-of-1 trials is rare as it has
the potential to be problematic. If a binary outcome is
measured only once within a period, there is a higher poten-
tial for residual effects to influence the next treatment, unless
sufficient washout can be guaranteed or carryover accounted
for in the analysis [109]. Readers should be mindful of this,
and authors should report measurement frequency, as indi-
cated in CENT item 6a.2. If binary outcomes are measured
Fig. 8. Results from Nonoyama et al. [32].
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thors should report absolute and relative effect sizes and
whether and how carryover effect was assessed or addressed.12.5. Ancillary analysis
Item 18
Standard CONSORT item: Results of any other ana-
lyses performed, including subgroup analyses and adjusted
analyses, distinguishing pre-specified from exploratory
CENT extension: Results of any other analyses per-
formed, including assessment of carryover effects, period
effects, and intra-subject correlation
Example: ‘‘Although there was an improvement over
time for the CRQ dyspnea (P5 0.05) and the CRQ mastery
(P 5 0.001), these effects were unrelated to the gas mixture
being used, with no main effects of oxygen, nor any inter-
action between treatment and pair for any of the CRQdomains. Furthermore, the upper boundary of the CI
excluded a mean difference greater than the MID for all
four CRQ domains (Table 2, Fig. 3). There were no signif-
icant differences between oxygen and placebo, or improve-
ments with time for any domains of the SGRQ.’’ [32].
Example: ‘‘The tests for carry-over effect disclosed no
significant differences in response measures in general or
in any of the subgroups.’’ [110].
In addition for series: if done, results of subgroup or
sensitivity analyses
Example: ‘‘We tested for interactions of treatment effect
and enrollment site (center vs. community) or any of the
selected patient characteristics. No statistically significant
associations were found in our study population (data not
shown). Additionally, no significant interactions between
time and treatment effect or between treatment order and
treatment effect were identified using random-effects
regression models (data not shown).’’ [89].
Fig. 9. Individual trial data from Avins et al. [108].
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subgroup or sensitivity analysis.
Explanation: In addition to analyses of treatment effects,
additional analyses may have been carried out, whether
stated a priori or not, to help authors further explore their
data. All such analyses, as well as whether they were
planned, should be reported. Additional analyses may
include a test for presence of carryover effect or period ef-
fect (see CENT item 12c) similar to those that might be car-
ried out for a crossover trial [96].
Where data from series of N-of-1 trials are quantitatively
synthesised, subgroup and sensitivity analyses as well as
meta-regression techniques may be used to explain heteroge-
neity and interpret the data and should be reported according
to the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) Guidelines [93,94].12.7. Harms
Item 19
StandardCONSORTitem:All harms or unintended effects
in each group (for specific guidance seeCONSORT for harms)Fig. 10. Individual trial data in a sCENT extensions: All harms or unintended effects for
each intervention (for specific guidance see CONSORT
for harms)
Example: ‘‘Only one adverse event-severe foot/ankle
swelling on celecoxib-resulted in withdrawal. Nine patients
reported more adverse events while on SR paracetamol than
on celecoxib, and five reported more while on celecoxib
than on SR paracetamol. In the other 25 patients, there
was no difference in the prevalence of adverse events re-
ported. The most common adverse events on celecoxib
were headache (54%), loss of energy (54%), indigestion
(36%) and constipation (32%); and on SR paracetamol
were loss of energy (51%), headache (49%) and constipa-
tion and indigestion (44%) (Table 5). There were differ-
ences between the two drugs in terms of stomach pain
(15% for celecoxib vs. 27% for SR paracetamol) and vom-
iting (2% for celebrex vs. 7% for SR paracetamol).’’ [111].
Explanation: N-of-1 trials are an important mechanism
for detecting harms that may uniquely occur in specific pa-
tients, which may or may not have been previously detected
in group trials or other epidemiological studies. In some in-
stances, an N-of-1 trial will have been designed specificallyeries from Zucker et al. [89].
Fig. 11. Series data from Nonoyama et al. [32].
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apy (for example, a patient with hypertension, asthma, and
a persistent cough undergoes a systematic N-of-1 evaluation
to confirm if his antihypertensive medication is causing the
cough). If the N-of-1 trial identifies a harm or otherwise un-
intended effect from the treatment administered, authors
must document this essential information in their trial report.
Specifically, the nature of each harm, its severity, along with
the period and treatment block during which it occurred
should be indicated. Equally, if no harms were detected, au-
thors should state that. Readers need information about
harms and lack of harms, in addition to information about
the benefits of interventions in order to make informed deci-
sions. Although serious harms are generally rare, reporting
harms is important even if they occur in a single patient.13. Discussion
13.1. Limitations
Item 20
Standard CONSORT item: Trial limitations, addressing
sources of potential bias and imprecision, and if relevant,
multiplicity of analysesFig. 12. Series data fromCENT extension: No change
Example: ‘‘A second limitation relates to the duration of
the trial; the long-term impact of the medication cannot be
addressed. A further limitation relates to the low number of
treatment pairs.’’ [112].
Explanation: See CONSORT item 20.13.2. Generalisability
Item 21
Standard CONSORT item: Generalisability (external
validity, applicability) of the trial findings
CENT extension: No change
Example: ‘‘The findings of this study are exploratory in
nature. Given the small sample size, these results should
not be generalised beyond the sample. The findings, howev-
er, suggest the potential benefit of TT for women with
migraine headaches. Participants in the study experienced
the beneficial effects of decreased migraine frequency and
increased relaxation levels in response to the TT interven-
tion, with no documented adverse effects. These findings
warrant further exploration of the effect of TT on more
diverse migraine headache populations and with a larger
sample.’’ [113].
Explanation: See CONSORT 2010 item 21.13.3. Interpretation
Item 22
Standard CONSORT item: Interpretation consistent
with results, balancing benefits and harms, and considering
other relevant evidence
CENT extension: No change
Example: ‘‘In other studies, 31 (72%) of 43 children had
a good response to methylphenidate, and 48 (68%) of 70
children showed improvement on methylphenidate in one
of two 2-week periods. Of 94 children treated with methyl-
phenidate, 70 (74%) demonstrated a positive response. Five
(50%) of 10 children with ADHD and IQs ranging from 48
to 77 responded positively to methylphenidate. OurCoxeter et al. [42].
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probably because of our different selection criteria and
more strict criteria for response. We also tested both meth-
ylphenidate and dexamphetamine against each other and
placebo, which none of the other studies did. In our study,
only 20% of the patients withdrew, which is much lower
than the withdrawal rates previously reported for N-of-1 tri-
als in Australia (40% and 37%). This may be related to our
ability to shorten the trials because stimulants are elimi-
nated so quickly from the body.’’ [114].
Explanation: The explanation for this item does not
differ from CONSORT item 22. Authors may also wish
to report whether the eventual treatment decision was
consistent with findings from the N-of-1 evaluation.14. Other information
14.1. Registration
Item 23
Standard CONSORT item: Registration number and
name of trial registry
CENT extension: No change
Example: ‘‘The study was registered in EudraCT data-
base under the number 2009-011736-35.’’ [115].
Explanation:
This item is no different from CONSORT 2010 item
23, although we feel that further explanation is warranted.
Much of the larger discussion around a priori study regis-
tration has focused on registration of group RCTs. The
registration of RCT protocols has substantially improved
over the past decade since the introduction of a mandatory
registration policy by ICMJE journals publishing trials
[116] and the US Food and Drug Administration [117].
Trial registration was essential to the initial characterisa-
tion of selective reporting of outcome in published RCTs,
now known to be a widespread problem [56]. Similarly,
registration of N-of-1 trials will allows readers to compare
a priori methods documented in registries against those in
a final report (published or not), if desired, to determine if
changes were made and whether they affect reported
findings.
Based on the pattern of early clinical trial registration,
it is thought that only a small proportion of clinically ori-
ented N-of-1 trials are registered and subsequently sub-
mitted for publication. Publication may or may not be
related to the favourability of the outcome of the trial,
risking the potential for publication bias [78]. Ideally, all
N-of-1 trials should be registered so readers can be aware
that they were conducted, even if not published. Ideally all
N-of-1 trials should be published so that they can become
part of the scientific record regardless of the outcome of
the trial.
Registration of N-of-1 trials may also inform the
improvement of methods and the development of study pro-
tocols for N-of-1 trials. The availability of N-of-1 trialprotocols is not yet commonplace, but existing databases
can accommodate the registration of N-of-1 trial protocols.
A recent systematic review indicates 97% of published tri-
als do not state whether a trial is registered, and only one
trial was identified in which registration details were pro-
vided in the report (see example above) [12]. Authors are
encouraged to register their N-of-1 trials before conducting
them, and including registration information (registry name
and unique identifier) in manuscripts submitted for journal
publication or public consumption.14.2. Protocol
Item 24
Standard CONSORT item: Where the full trial protocol
can be accessed, if available
CENT extension: No change
Example: ‘‘The protocol for this N-of-1 trial and sup-
porting CONSORT checklist are available as supporting
information; see Protocol S1 and Checklist S1.’’ [118].
Explanation: This item is no different from CONSORT
2010 item 24, but we have provided additional rationale
here. Trial protocols often contain more detailed informa-
tion than their accompanying registry entries. Increasingly,
the comparison of trial protocols (or registry entries) with
completed reports shows a plethora of changes to trial
design and outcomes, not always made clear by authors
in the final report, many of which represent a form of selec-
tive reporting bias [56]. For N-of-1 trials, the extent of this
problem is yet unknown. Authors are asked to indicate
where a protocol for the reported trial can be found.14.3. Funding
Item 25
Standard CONSORT item: Sources of funding and other
support (such as supply of drugs), role of funders
CENT extension: No change
Example: ‘‘Funding: this study was supported uncondi-
tionally by Leo Pharma, The Netherlands.’’ [29].
Explanation: See CONSORT 2010 item 25.15. Discussion
The CENT guidelines will allow decision-makers to
make better use of reported N-of-1 data. A standardised
approach to reporting of N-of-1 trials will facilitate
increased clarity in the communication of N-of-1 trial
methods, analysis, and outcomes. This will provide readers,
such as clinicians, with enough information to judge the
methodological rigor of the trial, whether treatment out-
comes may have been affected by bias, and, ultimately,
whether to employ an intervention in clinical practice.
N-of-1 trials have the potential to provide treatment in-
formation for patients who are typically excluded from
43L. Shamseer et al. / Journal of Clinical Epidemiology 76 (2016) 18e46evaluation in large scale RCTs, but good reporting is
crucial.
The CENT guidance will also improve the usability of
N-of-1 trial data by researchers, such as systematic re-
viewers, whose work in turn helps policymakers make de-
cisions about healthcare. Usability of primary evidence in
systematic reviews has been a longstanding, recognised
problem [119e121]. If well reported, N-of-1 trials are ideal
candidates for inclusion in systematic reviews since they
are a source of methodologically rigorous data on treatment
evaluation for patients who are often omitted from RCT
evaluation; doing so may broaden the applicability of sys-
tematic reviews. Furthermore, while the primary aim of
N-of-1 trials is not necessarily to provide generalisable
information, if they are more broadly representative and
are combined appropriately, they may be useful in making
decisions about healthcare policy where RCT data do not
apply or exist.
CENTwill allow other researchers and decisionmakers to
make better use of N-of-1 data. For instance, those respon-
sible for state or provincial or hospital formulary decision
making canmake better use of N-of-1 trials to help determine
which therapies should be eligible for coverage for specific
individuals, rather than the ‘‘all or none’’ approach that is
often used. When new uses for existing drugs emerge,
N-of-1 trials may be a quick and less expensive mechanism
with which to explore whether off label drug use might be
effective (that is, prior to or instead of a large scale RCT).
The availability of such evidence, if reported well, may also
be of use to regulators when making decisions about addi-
tional conditions of use for particular treatments.
The CENT guidelines may also have the potential to
affect the way that N-of-1 trials are designed before their
reporting becomes a consideration, if they are consulted
by researchers earlier in the research process. Furthermore,
if researchers adhere to newly developed standards of N-of-
1 design and implementation [11], which are in line with
CENT, compliance with CENT will be made easier.
Optimising the reporting of N-of-1 trials such that infor-
mation can be accurately and transparently gleaned from
them will increase their clinical value as an evaluation tool
for making evidence-based decisions and promoting
evidence-based practice.Acknowledgments
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